Interim Results - Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts – Daniela Bota
Use of ERC-1671 Vaccine in a patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
A Personalized immunotherapeutic vaccine (GLIOVAC or ERC1671) against recurrent glioma multiforme (GBM).
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.
Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation.